Literature DB >> 8555255

Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.

M Rudling1, V P Collins.   

Abstract

The current investigation aimed to determine if the gene expression of important structures in cholesterol metabolism is altered in a solid human tumor. For this purpose we determined low density lipoprotein (LDL) receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) transcript levels and total tissue cholesterol in both tumors and normal kidney tissue in a series of samples from 29 patients with renal cell carcinoma. (RCC). LDL-receptor- and HMG-CoA reductase mRNA levels were reduced in tumor tissue as compared with normal kidney tissue (by 29%, P < 0.03, and 31%, P < 0.001 respectively). The LDL-receptor mRNA levels correlated significantly to the mRNA levels for HMG-CoA reductase in tumors (P < 0.0001) and normal kidney tissue (P < 0.03). The total tissue cholesterol levels in tumors were 5-fold elevated (P < 0.0001) as compared to normal kidney. We conclude that the mRNA levels for LDL-receptor and HMG-CoA reductase are regulated in parallel in human RCC and in normal kidney, and that these mRNA are generally reduced in human RCC. The data indicate that the accumulation of cholesterol in RCC may not be due to increased LDL receptor expression or de novo synthesis of cholesterol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8555255     DOI: 10.1016/0005-2760(95)00195-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states.

Authors:  Amani Batarseh; Vassilios Papadopoulos
Journal:  Mol Cell Endocrinol       Date:  2010-06-30       Impact factor: 4.102

2.  Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation.

Authors:  M Rudling; M Gåfvels; P Parini; G Gahrton; B Angelin
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

3.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

4.  Anticancer activity of the cholesterol exporter ABCA1 gene.

Authors:  Bradley Smith; Hartmut Land
Journal:  Cell Rep       Date:  2012-09-13       Impact factor: 9.423

5.  Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma.

Authors:  Guang-Hua Xu; Ning Lou; Hang-Chuan Shi; Yu-Chen Xu; Hai-Long Ruan; Wen Xiao; Lei Liu; Xiang Li; Hai-Bing Xiao; Bin Qiu; Lin Bao; Chang-Fei Yuan; Ya-Li Zhou; Wen-Jun Hu; Ke Chen; Hong-Mei Yang; Xiao-Ping Zhang
Journal:  BMC Cancer       Date:  2018-01-22       Impact factor: 4.430

6.  Diagnostic and prognostic value of ABC transporter family member ABCG1 gene in clear cell renal cell carcinoma.

Authors:  Fucheng Meng; Yafei Xiao; Longxiang Xie; Qiao Liu; Keli Qian
Journal:  Channels (Austin)       Date:  2021-12       Impact factor: 2.581

7.  Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1-SREBP pathway.

Authors:  Yanhong Zhang; Shakur Mohibi; Demitria M Vasilatis; Mingyi Chen; Jin Zhang; Xinbin Chen
Journal:  Oncogene       Date:  2022-02-04       Impact factor: 8.756

8.  In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.

Authors:  F Süllentrop; J Hahn; D Moka
Journal:  Int J Biomed Sci       Date:  2012-06

9.  Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.

Authors:  Tasleem Arif; Oriel Stern; Srinivas Pittala; Vered Chalifa-Caspi; Varda Shoshan-Barmatz
Journal:  Cells       Date:  2019-10-28       Impact factor: 7.666

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.